These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1416837)

  • 1. Failure to adopt new interpretive criteria for ticarcillin-clavulanic acid could prove fatal.
    Sanders CC; Sanders WE; Thomson KS; Cavalieri SJ
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1343-4. PubMed ID: 1416837
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical trial of the efficacy and safety of ticarcillin and clavulanic acid.
    Roselle GA; Bode R; Hamilton B; Bibler M; Sullivan R; Douce R; Staneck JL; Bullock WE
    Antimicrob Agents Chemother; 1985 Mar; 27(3):291-6. PubMed ID: 3888101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disk diffusion susceptibility testing of ticarcillin plus clavulanic acid.
    Fuchs PC; Jones RN; Barry AL; Thornsberry C
    J Clin Microbiol; 1984 Apr; 19(4):555-7. PubMed ID: 6715524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reassessment of susceptibility test interpretive criteria for ticarcillin and ticarcillin-clavulanic acid.
    Fuchs PC; Jones RN; Barry AL
    J Clin Microbiol; 1989 Nov; 27(11):2475-81. PubMed ID: 2808671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholestasis with ticarcillin-potassium clavulanate (Timentin).
    Ryan J; Dudley FJ
    Med J Aust; 1992 Feb; 156(4):291. PubMed ID: 1738336
    [No Abstract]   [Full Text] [Related]  

  • 6. In vitro antibacterial activities of ticarcillin alone and ticarcillin plus clavulanic acid against beta-lactamase producing and non-producing microorganisms.
    Hsueh PR; Chang SC; Chen YC; Hsu LY; Luh KT; Hsieh WC
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1992 Aug; 25(3):149-59. PubMed ID: 1342000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibacterial activity of ticarcillin in the presence of clavulanate potassium.
    Sutherland R; Beale AS; Boon RJ; Griffin KE; Slocombe B; Stokes DH; White AR
    Am J Med; 1985 Nov; 79(5B):13-24. PubMed ID: 3878080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombocytosis and hyperkalemia associated with the use of ticarcillin/clavulanic acid.
    Moody SB; Pawlicki KS
    Drug Intell Clin Pharm; 1987 Mar; 21(3):292-3. PubMed ID: 3569032
    [No Abstract]   [Full Text] [Related]  

  • 9. Ticarcillin-clavulanic acid pharmacokinetics in preterm neonates with presumed sepsis.
    Burstein AH; Wyble LE; Gal P; Diaz PR; Ransom JL; Carlos RQ; Forrest A
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2024-8. PubMed ID: 7811013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypokalemia associated with ticarcillin-clavulanic acid.
    Titanji R; Trofa A
    Md Med J; 1993 Oct; 42(10):1013-4. PubMed ID: 8259044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bactericidal effects of ticarcillin-clavulanic acid against beta-lactamase-producing bacteria in vivo.
    Boon RJ; Beale AS; Sutherland R
    Antimicrob Agents Chemother; 1986 May; 29(5):838-44. PubMed ID: 3524431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of ticarcillin plus clavulanic acid against 632 clinical isolates.
    Fuchs PC; Barry AL; Thornsberry C; Jones RN
    Antimicrob Agents Chemother; 1984 Mar; 25(3):392-4. PubMed ID: 6721472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ticarcillin--clavulanic acid (Timentin).
    Med Lett Drugs Ther; 1985 Aug; 27(694):69-70. PubMed ID: 3894901
    [No Abstract]   [Full Text] [Related]  

  • 14. A controlled study of ticarcillin plus clavulanic acid versus piperacillin as empiric therapy for fever in the immunocompromised host.
    Williams ME; Harman C; Scheld M; Hess CE; Donowitz GR
    Am J Med; 1985 Nov; 79(5B):67-72. PubMed ID: 3907343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ticarcillin and ticarcillin-clavulanic acid susceptibility tests: error rates for disk tests with consecutively isolated members of the family Enterobacteriaceae.
    Barry AL; Fuchs PC; Gerlach EH; Hardy DJ; McLaughlin JC; Pfaller MA
    Antimicrob Agents Chemother; 1992 Jan; 36(1):137-43. PubMed ID: 1590679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of ticarcillin plus clavulanic acid in the treatment of infections of soft tissue, bone, and joint.
    Johnson CC; Reinhardt JF; Wallace SL; Terpenning MS; Helsel CL; Mulligan ME; Finegold SM; George WL
    Am J Med; 1985 Nov; 79(5B):136-40. PubMed ID: 4073081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noncomparative trial of ticarcillin plus clavulanic acid in skin and soft tissue infections.
    LeFrock JL; Johnson ES; Smith LG; Rosenberg E
    Am J Med; 1985 Nov; 79(5B):122-5. PubMed ID: 3907339
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical studies of BRL 28500 (clavulanic acid/ticarcillin) in the treatment of pelvioperitonitis and Douglas' abscess].
    Matsuda S; Suzuki M; Miyazaki R; Cho N; Kunii K; Fukunaga K; Hayashi S; Nakamura H; Tateno M; Okada H
    Jpn J Antibiot; 1987 May; 40(5):951-68. PubMed ID: 3499526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
    Qadri SM; Ueno Y; Cunha BA
    Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Piperacillin/tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infection.
    Shlaes DM; Baughman R; Boylen CT; Chan JC; Charan NB; Cormier YC; Erickson A; Grossman R; Kirmani N; Suh B
    J Antimicrob Chemother; 1994 Oct; 34(4):565-77. PubMed ID: 7868408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.